Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stock
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Amrutanjan Health Care Ltd (AMRUTANJAN) is currently trading at 582.55 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Amrutanjan Health Care Limited is an India-based consumer healthcare company primarily manufacturing and marketing over-the-counter wellness products across pain management, women’s hygiene, congestion relief and rehydration, supported by in-house fine chemicals capabilities and a legacy brand dating to the early 20th century, operating manufacturing plants near Chennai and a growing national distribution network. Q3 FY26 and YTD Dec’25 show sustained top-line momentum: Q3 net sales rose about 14.9% year-on-year and YTD net sales grew 11.5%, while YTD PBT expanded nearly 17.8%, indicating profitable growth driven by power brands Amrutanjan and Comfy and improved execution despite mixed performance in beverages and Electro+. Brand-level performance is divergent: flagship Amrutanjan (pain) delivered robust double-digit growth across head and body segments, Comfy (women’s hygiene) posted strong volume-led gains and premium SKU mix, while Electro+ rehydration and beverages experienced year-on-year declines, signaling category-specific weakness needing remedial focus from Amrutanjan Health Care Limited. Executional initiatives are material and measurable: distribution stockist network grew 6%, effective outlet coverage rose 10%, manpower increased 4%, and on-ground programs (rural van drives, sampling, high-impact TV tie-ups like Bigg Boss/KBC) plus quick-commerce expansion are being scaled to drive penetration and trials across urban and rural pockets. Financial housekeeping and revenue recognition nuances matter: IND AS 115 adjustments increased materially year-on-year, inflating gross sales add-backs for schemes and incentives, implying higher trade spends and potential margin pressure unless managed; management highlighted higher employee costs and advertising spend while pointing to reduced raw material prices except for marginal menthol increases.
Over the past 52 weeks, Amrutanjan Health Care Ltd has traded between a low of ₹490.00 and a high of ₹789.95. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Amrutanjan Health Care Ltd has a market capitalization of approximately 1,652.24. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Amrutanjan Health Care Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 40.47 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 1,652.24 Cr, Amrutanjan Health Care Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Amrutanjan Health Care Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Amrutanjan Health Care Ltd is 40.47. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Investor Presentation
Q1 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Amrutanjan Health Care Limited is an India-based consumer healthcare company primarily manufacturing and marketing over-the-counter wellness products across pain management, women’s hygiene, congestion relief and rehydration, supported by in-house fine chemicals capabilities and a legacy brand dating to the early 20th century, operating manufacturing plants near Chennai and a growing national distribution network.
Q3 FY26 and YTD Dec’25 show sustained top-line momentum: Q3 net sales rose about 14.9% year-on-year and YTD net sales grew 11.5%, while YTD PBT expanded nearly 17.8%, indicating profitable growth driven by power brands Amrutanjan and Comfy and improved execution despite mixed performance in beverages and Electro+.
Brand-level performance is divergent: flagship Amrutanjan (pain) delivered robust double-digit growth across head and body segments, Comfy (women’s hygiene) posted strong volume-led gains and premium SKU mix, while Electro+ rehydration and beverages experienced year-on-year declines, signaling category-specific weakness needing remedial focus from Amrutanjan Health Care Limited.
Executional initiatives are material and measurable: distribution stockist network grew 6%, effective outlet coverage rose 10%, manpower increased 4%, and on-ground programs (rural van drives, sampling, high-impact TV tie-ups like Bigg Boss/KBC) plus quick-commerce expansion are being scaled to drive penetration and trials across urban and rural pockets.
Financial housekeeping and revenue recognition nuances matter: IND AS 115 adjustments increased materially year-on-year, inflating gross sales add-backs for schemes and incentives, implying higher trade spends and potential margin pressure unless managed; management highlighted higher employee costs and advertising spend while pointing to reduced raw material prices except for marginal menthol increases.
Pharmaceuticals & Biotechnology
Pharmaceuticals
1,652 Cr
Low Risk
40.5
32.3
1.1
4.8
789.95
490.00
Sales CAGR
Profit CAGR
ROE
ROCE
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
771.55 | 1,862 Cr | 24.61 | 3.49 | 0.65 | 12.60 | 16.43 | 8.20 | ||
473.50 | 1,770 Cr | -98.49 | 1.42 | 0.00 | 0.51 | 5.47 | -0.83 | ||
1747.00 | 1,701 Cr | 32.08 | 5.88 | 0.00 | 16.91 | 18.84 | 11.83 | ||
569.75 | 1,652 Cr | 40.47 | 4.83 | 0.80 | 16.57 | 22.53 | 13.16 | ||
2329.00 | 1,405 Cr | 40.99 | 4.68 | 0.08 | 6.89 | 8.00 | 7.25 | ||
926.00 | 1,405 Cr | 16.22 | 2.36 | 0.00 | 10.66 | 13.99 | 9.93 | ||
33.48 | 1,385 Cr | 50.73 | 126.56 | 0.03 | — | — | 0.00 | ||
| Median: 7 Co. | — | 771.55 | 1,652 Cr | 32.08 | 4.68 | 0.03 | 11.63 | 15.21 | 8.20 |
